SC
CRSP icon

Stephens Consulting’s CRISPR Therapeutics CRSP Stock Holding History

Stephens Consulting’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$525 Hold
10
– – ﹤0.01% 427
2025
Q3 		$649 Hold
10
– – ﹤0.01% 367
2025
Q2 		$487 Hold
10
– – ﹤0.01% 908
2025
Q1 		$341 Hold
10
– – ﹤0.01% 1385
2024
Q4 		$394 Hold
10
– – ﹤0.01% 502
2024
Q3 		$470 Buy
+10
New +$507 ﹤0.01% 499

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
GP
GSK plc London $599M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stephens Consulting's CRSP Position: Q4 2025 in Review

Stephens Consulting held its CRISPR Therapeutics (CRSP) position steady in Q4 2025 at 10 shares worth $525. The position accounts for ﹤0.01% of the portfolio, ranked #427.

Stephens Consulting first reported a position in CRSP in Q3 2024 and has held it in 6 quarters since. The position peaked at $649 in Q3 2025. 479 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

  • Stephens Consulting held 10 shares of CRISPR Therapeutics worth $525 as of Q4 2025.
  • Stephens Consulting left its CRISPR Therapeutics share count unchanged in Q4 2025.
  • CRISPR Therapeutics made up ﹤0.01% of Stephens Consulting's portfolio in Q4 2025, its #427 holding.
  • Stephens Consulting first reported a position in CRISPR Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • Stephens Consulting's CRISPR Therapeutics position peaked at $649 in Q3 2025.
  • 479 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Stephens Consulting's 13F filing for Q4 2025, filed 13 Jan 2026.